[go: up one dir, main page]

SG11201603469UA - Compositions and methods for the treatment of viral diseases with pde4 modulators - Google Patents

Compositions and methods for the treatment of viral diseases with pde4 modulators

Info

Publication number
SG11201603469UA
SG11201603469UA SG11201603469UA SG11201603469UA SG11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA SG 11201603469U A SG11201603469U A SG 11201603469UA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
viral diseases
pde4 modulators
Prior art date
Application number
SG11201603469UA
Inventor
Jerome B Zeldis
Vikram Khetani
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201603469UA publication Critical patent/SG11201603469UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201603469UA 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators SG11201603469UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06
PCT/US2014/064047 WO2015069711A1 (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Publications (1)

Publication Number Publication Date
SG11201603469UA true SG11201603469UA (en) 2016-05-30

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603469UA SG11201603469UA (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Country Status (14)

Country Link
US (1) US20160289188A1 (en)
EP (1) EP3065778A1 (en)
JP (1) JP2016540041A (en)
KR (1) KR20160068981A (en)
CN (1) CN105873611A (en)
AR (1) AR099283A1 (en)
AU (1) AU2014346877A1 (en)
CA (1) CA2929539A1 (en)
EA (1) EA201690937A1 (en)
IL (1) IL245511A0 (en)
MX (1) MX2016005808A (en)
PH (1) PH12016500824A1 (en)
SG (1) SG11201603469UA (en)
WO (1) WO2015069711A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
CN1738614A (en) * 2002-11-18 2006-02-22 细胞基因公司 Compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide and how to use it
CN1452982A (en) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 Mucosa administrated Ribavirin prepn for preventing & curing SARS and its prepn process
KR20070007945A (en) * 2004-04-23 2007-01-16 셀진 코포레이션 Method of using PD4 modulator for the treatment and management of pulmonary hypertension and composition comprising the same
WO2007139150A1 (en) * 2006-05-30 2007-12-06 The University Of Tokushima ANTI-INFLUENZA VIRAL AGENT COMPRISING TNF-α INHIBITOR
EP2182805B1 (en) * 2007-08-27 2013-06-26 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
MX341050B (en) * 2010-04-07 2016-08-05 Celgene Corp * Methods for treating respiratory viral infection.
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
JP2016540041A (en) 2016-12-22
MX2016005808A (en) 2016-07-18
EP3065778A1 (en) 2016-09-14
CA2929539A1 (en) 2015-05-14
PH12016500824A1 (en) 2016-06-13
IL245511A0 (en) 2016-06-30
US20160289188A1 (en) 2016-10-06
WO2015069711A1 (en) 2015-05-14
EA201690937A1 (en) 2017-02-28
KR20160068981A (en) 2016-06-15
AR099283A1 (en) 2016-07-13
CN105873611A (en) 2016-08-17
AU2014346877A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and compositions for the treatment of cancer
IL240213A0 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IL243348A0 (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1
IL236700A0 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
EP2988781A4 (en) Compositions and methods for the therapy and diagnosis of influenza
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3003391A4 (en) Adeno-associated virus variants and methods of use thereof
HUE041553T2 (en) Methods and compositions for the treatment of monogenic diseases
GB201320723D0 (en) Composition and methods of treatment
SG11201601416VA (en) Novel sez6 modulators and methods of use
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PL3466425T3 (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
EP3086809A4 (en) Compositions and methods of treating ocular diseases
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP2934501A4 (en) Uses and methods for the treatment of liver diseases or conditions
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201315072D0 (en) Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
PL3079684T3 (en) Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
IL245511A0 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
HK40114296A (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1